18-Mar-2025 9:34 AM CST - Yahoo Finance Insulet Chief Technology Officer Mark Field leaves Insulet Chief Technology Officer Mark Field left the company on Friday to pursue other opportunities, according to a Monday securities filing. Amit Guliani, Insulet's group vice president of software engineering,
11-Mar-2025 12:57 PM CST - Yahoo Finance Insulet (NasdaqGS:PODD) Declines 12% After Earnings Reveal Net Income Decrease Insulet (NasdaqGS:PODD) experienced a 12% decline in its stock price over the past week following its earnings announcement and corporate guidance. The company reported strong year-over-year sales growth,
11-Mar-2025 5:00 AM CST - Business Wire Insulet to Host Investor Day on June 5, 2025 Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, will host an Investor Day at the Company's global headquarters in Acton, Massachusetts on Thursday, June 5, 2025. Presentations will be led by Jim Hollingshead, President and CEO, members of the Executive Leadership Team, and independent experts. The agenda will include a comprehensive overview of the Companys lea
4-Mar-2025 5:57 AM CST - Business Insider Wells Fargo Sticks to Its Buy Rating for Insulet (PODD) In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Insulet (PODD - Research Report), with a price
27-Feb-2025 8:16 PM CST - Morningstar Insulet's Distinctive Omnipod Pump Makes Inroads With Large Type 2 Diabetes Segment Until Insulet's Omnipod came on the market at the end of 2005, all insulin pumps consisted of a controller and insulin reservoir attached to the injection site by a long flexible tube. The Omnipod design eliminates the tubing,
25-Feb-2025 6:55 AM CST - MSN Insulet Stock Outlook: Is Wall Street Bullish or Bearish? Insulet Corporation (PODD), headquartered in Acton, Massachusetts, operates as an innovative medical device company. Valued at $19.8 billion by market cap, the company develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes.
24-Feb-2025 5:26 AM CST - Business Insider Insulet price target raised to $335 from $315 at Bernstein Bernstein raised the firm's price target on Insulet (PODD) to $335 from $315 following a strong quarter and an "impressive" outside-U.S.
21-Feb-2025 6:38 AM CST - Business Insider Insulet (PODD) Receives a Hold from Stifel Nicolaus Stifel Nicolaus analyst Mathew Blackman maintained a Hold rating on Insulet (PODD - Research Report) today and set a price target of $293.00.
18-Mar-2025 9:34 AM CST - Yahoo Finance Insulet Chief Technology Officer Mark Field leaves Insulet Chief Technology Officer Mark Field left the company on Friday to pursue other opportunities, according to a Monday securities filing. Amit Guliani, Insulet's group vice president of software engineering,
11-Mar-2025 12:57 PM CST - Yahoo Finance Insulet (NasdaqGS:PODD) Declines 12% After Earnings Reveal Net Income Decrease Insulet (NasdaqGS:PODD) experienced a 12% decline in its stock price over the past week following its earnings announcement and corporate guidance. The company reported strong year-over-year sales growth,
11-Mar-2025 5:00 AM CST - Business Wire Insulet to Host Investor Day on June 5, 2025 Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, will host an Investor Day at the Company's global headquarters in Acton, Massachusetts on Thursday, June 5, 2025. Presentations will be led by Jim Hollingshead, President and CEO, members of the Executive Leadership Team, and independent experts. The agenda will include a comprehensive overview of the Companys lea
4-Mar-2025 5:57 AM CST - Business Insider Wells Fargo Sticks to Its Buy Rating for Insulet (PODD) In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Insulet (PODD - Research Report), with a price
27-Feb-2025 8:16 PM CST - Morningstar Insulet's Distinctive Omnipod Pump Makes Inroads With Large Type 2 Diabetes Segment Until Insulet's Omnipod came on the market at the end of 2005, all insulin pumps consisted of a controller and insulin reservoir attached to the injection site by a long flexible tube. The Omnipod design eliminates the tubing,
25-Feb-2025 6:55 AM CST - MSN Insulet Stock Outlook: Is Wall Street Bullish or Bearish? Insulet Corporation (PODD), headquartered in Acton, Massachusetts, operates as an innovative medical device company. Valued at $19.8 billion by market cap, the company develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes.
24-Feb-2025 5:26 AM CST - Business Insider Insulet price target raised to $335 from $315 at Bernstein Bernstein raised the firm's price target on Insulet (PODD) to $335 from $315 following a strong quarter and an "impressive" outside-U.S.
21-Feb-2025 6:38 AM CST - Business Insider Insulet (PODD) Receives a Hold from Stifel Nicolaus Stifel Nicolaus analyst Mathew Blackman maintained a Hold rating on Insulet (PODD - Research Report) today and set a price target of $293.00.
